

CITATION REPORT

List of articles citing

Management of Crohn's disease in adults

DOI: 10.1038/ajg.2008.168

American Journal of Gastroenterology, 2009, 104,
465-83; quiz 464, 484.

Source: <https://exaly.com/paper-pdf/47107640/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
750	Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update. <i>Clinical and Experimental Gastroenterology</i> , 2009 , 149	3.1	
749	Tratamento da doena de Crohn com infliximabe: primeira opo. 2009 , 22, 101-104		1
748	An evidence-based review of natalizumab therapy in the management of Crohn's disease. 2009 , 5, 935-42		6
747	Certolizumab pegol for the management of Crohn's disease in adults. 2009 , 31, 1158-76		30
746	Clinical significance of inflammatory markers. 2009 , 11, 360-7		5
745	Managing the risks of IBD therapy. 2009 , 11, 509-17		5
744	Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey. 2009 , 30, 854-863		8
743	Medical management of Crohn's disease: treatment algorithms 2009. 2009 , 27, 536-41		9
742	Inflammatory bowel disease in the elderly. 2009 , 38, 447-62		22
741	Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. 2009 , 38, 577-94		19
740	Perspective: Conflict of interest and professional organizations: considerations and recommendations. 2010 , 85, 85-91		20
739	Preparing the patient for immunosuppressive therapy. 2010 , 12, 502-6		5
738	Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn's disease. 2010 , 14, 1859-65; discussion 1865-6		83
737	Do non-steroidal anti-inflammatory drugs cause exacerbations of inflammatory bowel disease?. 2010 , 55, 226-32		33
736	Biologic agent use varies inversely with age at diagnosis in Crohn's disease. 2010 , 55, 3164-70		5
735	Anti-inflammatory arene--chromium complexes acting as specific inhibitors of NOD2 signalling. 2010 , 5, 2065-71		25
734	Improving quality of care in IBD: a STEEEP challenge. 2010 , 16, 134-6		6

733	Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. 2010 , 16 Suppl 1, S1-11	14
732	Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. 2010 , 31, 1296-309	78
731	Systematic review: steroid withdrawal in anti-TNF-treated patients with inflammatory bowel disease. 2010 , 32, 313-23	12
730	The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. 2010 , 32, 1228-39	112
729	Ulcerative Colitis. 2010 , 304-311	
728	Lifestyle-related disease in Crohn's disease: relapse prevention by a semi-vegetarian diet. 2010 , 16, 2484-95	136
727	Locking the Door to Leukocytes: Use of Integrin Inhibitors for the Treatment of Crohn's Disease. 2010 , 2, CMT.S4013	
726	Small-bowel capsule endoscopy in patients with suspected Crohn's disease-diagnostic value and complications. 2010 , 2010,	19
725	Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. 2010 , 59, 752-9	133
724	Decision-making in ileocecal Crohn's disease management: surgery versus pharmacotherapy. 2010 , 4, 181-9	11
723	Natalizumab for the treatment of Crohn's disease. 2010 , 6, 513-9	11
722	Early Crohn disease: a proposed definition for use in disease-modification trials. 2010 , 59, 141-7	88
721	Therapy Adherence in Crohn's Disease: An Adult Case Study. 2010 , 4, 153-157	
720	Current therapeutic approaches in inflammatory bowel disease. 2010 , 16, 3668-83	25
719	Serologic markers: impact on early diagnosis and disease stratification in inflammatory bowel disease. 2010 , 122, 177-85	11
718	Crohn's disease is a risk factor for preterm birth. 2010 , 8, 509-15	90
717	Tumor necrosis factor- α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology. 2010 , 39, 543-57	33
716	How genetic variation affects patient response and outcome to therapy for psoriasis. 2010 , 6, 957-66	18

715	What is the optimal therapy for Crohn's disease: step-up or top-down?. 2010 , 4, 167-80		31
714	Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. 2010 , 24 Suppl 1, 3-14		71
713	Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. 2010 , 94, 1-18		26
712	Infliximab, azathioprine, or combination therapy for Crohn's disease. 2010 , 362, 1383-95		2198
711	Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. 2010 , 8, 688-695.e2		126
710	Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. <i>American Journal of Gastroenterology</i> , 2010 , 105, 1142-9	0.7	75
709	Appropriateness of early management of newly diagnosed Crohn's disease in a European population-based cohort. 2010 , 45, 1449-56		5
708	Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. 2011 , 9, 670-678.e3		117
707	A Crohn's disease patient who does not respond to infliximab: what is next?. 2011 , 9, 1033-8		3
706	Inflammatory bowel disease: perioperative pharmacological considerations. 2011 , 86, 748-57		33
705	Crohn's disease of the ileal pouch 16 years after proctocolectomy for ulcerative colitis. 2011 , 9, 198-201		3
704	Conventional medical management of inflammatory bowel disease. 2011 , 140, 1827-1837.e2		164
703	Capsule endoscopy for small-bowel evaluation in Crohn's disease. 2011 , 74, 167-75		47
702	An evidence-based systematic review on medical therapies for inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2011 , 106 Suppl 1, S2-25; quiz S26	0.7	205
701	A practical, evidence-based guide to the use of adalimumab in Crohn's disease. 2011 , 27, 1803-13		6
700	Epstein-Barr virus replication linked to B cell proliferation in inflamed areas of colonic mucosa of patients with inflammatory bowel disease. 2011 , 50, 31-6		32
699	Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. 2011 , 17, 4166-73		53
698	Nutritional problems in inflammatory bowel disease patients. 2011 , 2, 69-77		1

697	Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn's disease: a meta-analysis. 2011 , 25, 492-6	29
696	Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn's disease. 2011 , 23, 1100-10	38
695	Leisure-time physical activity in Canadians living with Crohn disease and ulcerative colitis: population-based estimates. 2011 , 34, 288-94	22
694	Development of spectral markers for the discrimination of ulcerative colitis and Crohn's disease using Raman spectroscopy. 2011 , 54, 48-53	30
693	Inflammatory bowel disease therapy: current state-of-the-art. 2011 , 27, 346-57	30
692	Review article: the role of non-biological drugs in refractory inflammatory bowel disease. 2011 , 33, 417-27	24
691	Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. 2011 , 33, 541-50	37
690	Review article: infliximab for Crohn's disease treatment--shifting therapeutic strategies after 10 years of clinical experience. 2011 , 33, 857-69	60
689	Review article: remission rates achievable by current therapies for inflammatory bowel disease. 2011 , 33, 870-9	111
688	Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol. 2011 , 33, 1143-51	7
687	Lack of increased prevalence of immunoregulatory disorders in hereditary angioedema due to C1-inhibitor deficiency. 2011 , 141, 58-66	21
686	Existing dietary guidelines for Crohn's disease and ulcerative colitis. 2011 , 5, 411-25	71
685	Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial. 2011 , 56, 2088-97	80
684	A review of major Crohn's disease susceptibility genes and their role in disease pathogenesis. 2011 , 33, 317-325	4
683	Update on the management of Crohn's disease. 2011 , 13, 465-74	22
682	Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn's disease: good safety profile but lack of efficacy. 2011 , 17, 573-82	59
681	Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn's disease. 2011 , 17, 1073-80	165
680	Inflammatory Bowel Disease. 2011 ,	2

679	Update on the management of inflammatory bowel disease: specific role of adalimumab. <i>Clinical and Experimental Gastroenterology</i> , 2011 , 4, 163-72	3.1	23
678	Current and future role of biomarkers in Crohn's disease risk assessment and treatment. <i>Clinical and Experimental Gastroenterology</i> , 2011 , 4, 127-40	3.1	16
677	Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. 2011 , 60, 930-6		177
676	Jaundice and rectal bleeding in a young man. 2011 , 60, 892, 936		1
675	Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change. 2011 , 60, 1754-63		92
674	Azathioprine and Infliximab: Monotherapy or Combination Therapy in the Treatment of Crohn's Disease. 2011 , 4, CGast.S5256		1
673	5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2011 , 106, 413-20	0.7	82
672	Medication Repurposing: New Uses for Old Drugs. 2011 , 27, 132-140		5
671	Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2011 , 106, 630-42	0.7	183
670	Maternal-Fetal Evidence Based Guidelines. 2011 ,		3
669	Stability of infliximab dosing in inflammatory bowel disease: results from a multicenter US chart review. 2011 , 14, 397-402		8
668	Certolizumab pegol for the treatment of Crohn's disease. 2011 , 4, 375-89		48
667	Colicin-like bacteriocins as novel therapeutic agents for the treatment of chronic biofilm-mediated infection. 2012 , 40, 1549-52		23
666	Sonographic Findings in a Case of Crohn Disease. 2012 , 28, 80-87		
665	Gastrointestinal delivery of anti-inflammatory nanoparticles. 2012 , 509, 101-25		28
664	Resource utilization before and during infliximab therapy in patients with inflammatory bowel disease. 2012 , 15, 45-52		10
663	Patient adherence and efficacy of certolizumab pegol in the management of Crohn's disease. 2012 , 5, 11-21		2
662	Budesonide use in pediatric Crohn disease. 2012 , 55, 200-4		5

661	Chirurgie des maladies inflammatoires chroniques de l'intestin. 2012 , 7, 1-13		
660	Does preoperative immunosuppression influence unplanned hospital readmission after surgery in patients with Crohn's disease?. 2012 , 55, 563-8		16
659	Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey. 2012 , 57, 3080-91		61
658	An update of the role of nutritional therapy in the management of Crohn's disease. 2012 , 47, 872-82		32
657	Cytomegalovirus pneumonia in patients with inflammatory bowel disease: a systematic review. 2012 , 16, e474-9		20
656	Gastroenterologists and the triple aim: how to become accountable. 2012 , 22, 85-96		5
655	Using germline genomics to individualize pediatric cancer treatments. 2012 , 18, 2791-800		16
654	Systems analysis of inflammatory bowel disease based on comprehensive gene information. 2012 , 13, 25		5
653	Diarrhea in chronic inflammatory bowel diseases. 2012 , 41, 651-75		23
652	Myelosuppression monitoring after immunomodulator initiation in veterans with inflammatory bowel disease: a national practice audit. 2012 , 36, 1049-56		7
651	Pharmacogenomics of Inflammatory Bowel Diseases. 2012 , 323-351		
650	Implementing changes in clinical practice to improve the management of Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2012 , 6 Suppl 2, S235-42	1.5	16
649	Small bowel endoscopy in inflammatory bowel disease. 2012 , 26, 279-91		10
648	Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: results from an international survey and discussion programme. <i>Journal of Crohn's and Colitis</i> , 2012 , 6, 116-31	1.5	13
647	Pneumocystosis in a patient with Crohn's disease treated with combination therapy with adalimumab. <i>Journal of Crohn's and Colitis</i> , 2012 , 6, 483-7	1.5	7
646	Thiopurine treatment in inflammatory bowel disease: response predictors, safety, and withdrawal in follow-up. <i>Journal of Crohn's and Colitis</i> , 2012 , 6, 588-96	1.5	41
645	Gastrointestinal Diseases. 2012 ,		
644	How I do it: Side-to-side isoperistaltic strictureplasty for extensive Crohn's disease. 2012 , 16, 1976-80		7

- 643 Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. **2012**, 10, 1002-7; quiz e78 168
- 642 Let's get personal: predicting thiopurine and fluoropyrimidine toxicity. **2012**, 9, 859-870
- 641 Methotrexate: underused and ignored?. **2012**, 30 Suppl 3, 112-8 15
- 640 Interleukin-11 for induction of remission in Crohn's disease. **2012**,
- 639 Anti-IL-17 monoclonal antibody for induction of remission in Crohn's disease. **2012**,
- 638 Inflammatory Bowel Disease. **2012**, 913-921 1
- 637 Concordance in action: case study of medication management. **2012**, 10, 195-200 1
- 636 Rare association of polyneuropathy and Crohn's disease: a clinicopathological study of 4 cases. **2012**, 63, 261-6 6
- 635 Bezoar by mesalazine tablets: cause of intestinal obstruction in Crohn's disease. **2012**, 32, 422-425 2
- 634 Patient perspectives on the impact of Crohn's disease: results from group interviews. **2012**, 6, 509-20 22
- 633 Effect of a continuous measure of adherence with infliximab maintenance treatment on inpatient outcomes in Crohn's disease. **2012**, 6, 417-26 13
- 632 Efficacy of Early Infliximab Treatment for Pediatric Crohn's Disease: A Three-year Follow-up. **2012**, 15, 243-9 11
- 631 [Guidelines for the management of Crohn's disease]. **2012**, 59, 141-79 16
- 630 The role of anti(myco)bacterial interventions in the management of IBD: is there evidence at all?. **2012**, 30, 358-67 12
- 629 Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. **2012**, 18, 1057-63 38
- 628 Serum analysis of tryptophan catabolism pathway: correlation with Crohn's disease activity. **2012**, 18, 1214-20 80
- 627 Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease. **2012**, 18, 1608-16 32
- 626 Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis. **2012**, 18, 2034-42 50

625	Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data. 2012 , 18, 2225-31	52
624	Cost-utility analysis of biologic treatments for moderate-to-severe Crohn's disease. 2012 , 32, 515-26	26
623	Have genomic discoveries in inflammatory bowel disease translated into clinical progress?. 2012 , 14, 139-45	6
622	Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy. 2012 , 36, 312-23	56
621	Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients. 2012 , 36, 569-74	44
620	Poor recall of prior exposure to varicella zoster, rubella, measles, or mumps in patients with IBD. 2013 , 19, 418-22	20
619	Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease. 2013 , 37, 1172-83	39
618	Recent advances using immunomodulators for inflammatory bowel disease. 2013 , 53, 575-88	30
617	New strategies for the treatment of inflammatory bowel diseases. 2013 , 3, 479-492	
616	Vedolizumab as induction and maintenance therapy for Crohn's disease. 2013 , 369, 711-21	1328
615	Tumor necrosis factor inhibitors for inflammatory bowel disease. 2013 , 369, 754-62	225
614	Management of active Crohn disease. 2013 , 309, 2150-8	90
613	American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. 2013 , 145, 1464-78.e1-5	95
612	Magnetic resonance enterography: inflammatory bowel disease and beyond. 2013 , 21, 731-50	15
611	Preventing postoperative recurrence in Crohn's disease: what does the future hold?. 2013 , 73, 1749-59	21
610	Comparing guidelines for the treatment of inflammatory bowel disease. 2013 , 31, 360-2	
609	Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease. 2013 , 38, 255-63	90
608	Comparative effectiveness of anti-TNF agents for Crohn's disease in a tertiary referral IBD practice. 2013 , 58, 209-15	19

607	Accuracy of small-intestine contrast ultrasonography, compared with computed tomography enteroclysis, in characterizing lesions in patients with Crohn's disease. 2013 , 11, 950-5		47
606	Is there still a role for thiopurines in Crohn's disease?. 2013 , 145, 714-6		10
605	Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis. 2013 , 107, 1797-802		15
604	How to achieve deep remission in treatment of inflammatory bowel disease. 2013 , 33, 549-52		
603	Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease. 2013 , 11, 1281-7		18
602	Diarrhea as sole presentation of Good's syndrome mimicking Crohn's disease. 2013 , 147, 9-10		3
601	Toxicity after (125)I prostate brachytherapy in patients with inflammatory bowel disease. 2013 , 12, 126-33		21
600	Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials. <i>Journal of Crohns and Colitis</i> , 2013 , 7, 958-67	1.5	11
599	Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II study. <i>Journal of Crohns and Colitis</i> , 2013 , 7, 239-47	1.5	35
598	Crohn's disease recurrence in patients with ileocolic anastomosis: value of computed tomography enterography with water enema. 2013 , 82, e434-40		14
597	Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial. <i>Journal of Crohns and Colitis</i> , 2013 , 7, 34-43	1.5	38
596	Traitement chirurgical de la rectocolite hémorragique. 2013 , 7, 27-34		
595	The role of antimicrobials in Crohn's disease. 2013 , 7, 281-8		12
594	Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab. 2013 , 11, 975-81.e1-4		132
593	First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?. 2013 , 10, 345-51		46
592	Achievement of deep remission during scheduled maintenance therapy with TNF blocking agents in IBD. <i>Journal of Crohns and Colitis</i> , 2013 , 7, 730-5	1.5	79
591	The risks of post-operative complications following pre-operative infliximab therapy for Crohn's disease in patients undergoing abdominal surgery: a systematic review and meta-analysis. <i>Journal of Crohns and Colitis</i> , 2013 , 7, 868-77	1.5	77
590	Immunization status in children with inflammatory bowel disease. 2014 , 173, 603-8		8

589	WITHDRAWN: Dual Therapy With Infliximab and Immunomodulator Reduces 1-Year Rates of Hospitalization and Surgery Among Veterans With Inflammatory Bowel Disease. 2013,	
588	Bone loss in patients with the ileostomy and ileal pouch for inflammatory bowel disease. 2013, 1, 159-65	8
587	Surgical management of IBD--from an open to a laparoscopic approach. 2013, 10, 297-306	34
586	Hepatitis B virus reactivation induced by infliximab administration in a patient with Crohn's disease. 2013, 2013, 461879	4
585	The management of immunosuppression in patients with inflammatory bowel disease and cancer. 2013, 62, 1523-8	41
584	A systematic review of economic studies on biological agents used to treat Crohn's disease. 2013, 19, 2673-94	28
583	6-Thioguanine levels in pediatric IBD patients: adherence is more important than dose. 2013, 19, 2652-8	14
582	Probiotics and Inflammatory Bowel Diseases. 2013, 39, 8-9	1
581	Progressing the utilisation of pharmacogenetics and pharmacogenomics into clinical care. 2013, 45, 357-70	3
580	The incidence and predictors of lupus-like reaction in patients with IBD treated with anti-TNF therapies. 2013, 19, 2778-86	17
579	Clinical Nutrition INSIGHT. 2013, 39, 10-11	
578	newsbites. 2013, 39, 12	
577	Exploring associations of 6-thioguanine nucleotide levels and other predictive factors with therapeutic response to azathioprine in pediatric patients with IBD using multilevel analysis. 2013, 19, 2404-10	15
576	Dietary Interventions for Inflammatory Bowel Disease. 2013, 39, 5-7	
575	Probiotics and Pouchitis. 2013, 39, 9-11	
574	Dietary fiber information for individuals with Crohn disease: reports of gastrointestinal effects. 2013, 36, 320-7	7
573	Review of the use of intralesional steroid injections in the management of ileocolonic Crohn's strictures. 2013, 4, 238-243	6
572	Comparative outcomes of younger and older hospitalized patients with inflammatory bowel disease treated with corticosteroids. 2013, 19, 2644-51	6

571	Interactions Between Diet and Gut Microbes in Inflammatory Bowel Disease. 2013 , 39, 1-5	
570	Addition of thiopurines can recapture response in patients with Crohn's disease who have lost response to anti-tumor necrosis factor monotherapy. 2013 , 28, 1595-9	33
569	Practical medical management of Crohn's disease. 2013 , 2013, 208073	12
568	Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors. 2013 , 38, 1188-97	61
567	Advances in the Management of Inflammatory Bowel Disease. 2013 ,	
566	Medical management of Crohn's disease. 2013 , 104-122	
565	Neutrophilic dermatosis after azathioprine exposure. 2013 , 149, 592-7	26
564	The employee absenteeism costs of inflammatory bowel disease: evidence from US National Survey Data. 2013 , 55, 393-401	25
563	Prevention of postoperative recurrence of Crohn's disease: what does the evidence support?. 2013 , 19, 856-9	19
562	Fecal microbiota transplantation for severe enterocolonic fistulizing Crohn's disease. 2013 , 19, 7213-6	81
561	Docosahexaenoic acid, inflammation, and bacterial dysbiosis in relation to periodontal disease, inflammatory bowel disease, and the metabolic syndrome. 2013 , 5, 3299-310	31
560	Impact of Magnetic Resonance Imaging in Management of Pediatric Crohn's Disease. 2013 , 79, 672-675	2
559	5-Aminosalicylates reduce the risk of colorectal neoplasia in patients with ulcerative colitis: an updated meta-analysis. 2014 , 9, e94208	49
558	IDO1 and IDO2 non-synonymous gene variants: correlation with crohn's disease risk and clinical phenotype. 2014 , 9, e115848	20
557	Crohn's disease in Korea: past, present, and future. 2014 , 29, 558-70	22
556	Defining quality indicators for best-practice management of inflammatory bowel disease in Canada. 2014 , 28, 275-85	39
555	Psychosocial issues in evidence-based guidelines on inflammatory bowel diseases: a review. 2014 , 20, 3663-71	45
554	A guide to prepare patients with inflammatory bowel diseases for anti-TNF- α therapy. 2014 , 20, 487-98	23

553	Small intestinal bacterial overgrowth in inactive Crohn's disease: influence of thiopurine and biological treatment. 2014 , 20, 13999-4003	24
552	Crohn Disease And The Specialty Pharmacist. 2014 , 20, 42-43	
551	. 2014 ,	1
550	Immunosuppressive agents. 2014 , 100-116	
549	The cost-effectiveness of infliximab in Crohn's disease. 2014 , 14, 589-98	5
548	Thiopurines and myeloid disorders: is more caution needed when treating inflammatory bowel disease patients?. 2014 , 10, 1563-5	1
547	The role of latanoprost in an inflammatory bowel disease flare. 2014 , 2, 232-4	5
546	[Therapy of Inflammatory Bowel Disease]. <i>Praxis</i> , 2014 , 103, 203-11	0.1
545	Methodological quality of guidelines in gastroenterology. 2014 , 46, 513-25	10
544	Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease. 2014 , 30, 1821-6	7
543	Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's disease. 2014 , 14, 599-609	1
542	Colorectal cancer in inflammatory bowel disease: a shift in risk?. 2014 , 14, 847-56	5
541	Isolated gastroduodenal Crohn's disease in a septuagenarian man. 2014 , 46 Suppl 1 UCTN, E167-8	1
540	East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. 2014 , 63, 588-97	246
539	Review article: the psychosexual impact of inflammatory bowel disease in male patients. 2014 , 39, 1085-94	22
538	Allopurinol enhanced thiopurine treatment for inflammatory bowel disease: safety considerations and guidelines for use. 2014 , 39, 107-11	11
537	Endoscopy-coupled Raman spectroscopy for in vivo discrimination of inflammatory bowel disease. 2014 ,	5
536	Chronic inflammation and quality of life in older adults: a cross-sectional study using biomarkers to predict emotional and relational outcomes. 2014 , 12, 141	37

535	The role of thiopurine metabolite monitoring in inflammatory bowel disease. 2014 , 8, 383-92	11
534	Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease. 2014 , 48, 423-9	48
533	Surgical treatment of complex small bowel Crohn disease. 2014 , 260, 230-5	15
532	A nationwide 2010-2012 analysis of U.S. health care utilization in inflammatory bowel diseases. 2014 , 20, 1747-53	46
531	Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD. 2014 , 20, 1714-21	72
530	Menstrual cycle changes in women with inflammatory bowel disease: a study from the ocean state Crohn's and colitis area registry. 2014 , 20, 534-40	26
529	Azathioprine-Induced Rapid Hepatotoxicity. 2014 , 30, 18-20	3
528	Gut microbiota and inflammatory bowel disease: the role of antibiotics in disease management. 2014 , 126, 7-19	192
527	The role of thiopurine metabolites in inflammatory bowel disease and rheumatological disorders. 2014 , 17, 132-41	9
526	Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease. 2014 , 12, 1324-9	61
525	Herpes simplex virus blepharitis in a patient with Crohn's colitis. 2014 , 127, e1-2	3
524	Evaluation of Crohn's disease activity: initial validation of a magnetic resonance enterography global score (MEGS) against faecal calprotectin. 2014 , 24, 277-87	86
523	Steroid use in Crohn's disease. 2014 , 74, 313-24	7
522	New magnetic resonance imaging modalities for Crohn disease. 2014 , 22, 35-50	14
521	Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine. <i>Journal of Crohn's and Colitis</i> , 2014 , 8, 384-91	1.5 42
520	Efficacy and safety of sulfasalazine in patients with chronic idiopathic urticaria. 2014 , 112, 64-70	26
519	Addressing current treatment challenges in Crohn's disease in real life: a physician's survey. 2014 , 46, 1066-71	3
518	MR imaging of distal ileal and colorectal chronic inflammatory bowel disease--diagnostic accuracy of 1.5 T and 3 T MRI compared to colonoscopy. 2014 , 29, 1541-50	15

517	Vedolizumab: an $\alpha 4 \beta 7$ integrin inhibitor for inflammatory bowel diseases. 2014 , 48, 1629-35		13
516	Clinical implications of ageing for the management of IBD. 2014 , 11, 128-38		33
515	Monoclonal Antibodies in Phase 1 and 2 Studies for Immunological Disorders. 2014 , 927-968		
514	Update on anti-tumor necrosis factor agents in Crohn disease. 2014 , 43, 457-78		31
513	Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1055-64	0.7	105
512	Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. 2014 , 63, 919-27		34 ^o
511	Magnetic resonance imaging and clinical assessments for perianal Crohn's disease: gain and limits. 2014 , 46, 1072-6		10
510	Chromoendoscopy for colorectal cancer surveillance in patients with inflammatory bowel disease. 2014 , 16, 407		8
509	6-Mercaptopurine/Azathioprine remains an important contributor in managing Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2014 , 8, 735-8	1.5	2
508	Toward a consensus on endoscopic surveillance of patients with colonic inflammatory bowel disease. 2014 , 24, 469-81		15
507	Advanced endoscopic imaging techniques in Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2014 , 8, 261-9.5		24
506	Medical management of inflammatory bowel disease in the elderly: balancing safety and efficacy. 2014 , 30, 67-78		10
505	Clinical trials in luminal Crohn's disease: a historical perspective. <i>Journal of Crohn's and Colitis</i> , 2014 , 8, 1339-50	1.5	20
504	Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis. 2014 , 12, 1793-1800.e1		49
503	Crohn's disease masquerading as an acute abdomen. 2014 , 28, 444-50		
502	Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. 2014 , 147, 618-627.e3		468
501	The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease. 2014 , 43, 525-41		34
500	Treatment algorithms in Crohn's - up, down or something else?. 2014 , 28, 473-83		25

499	Safety and efficacy of endoscopic dilation for primary and anastomotic Crohn's disease strictures. <i>Journal of Crohns and Colitis</i> , 2014 , 8, 392-400	1.5	68
498	Switching from insulin to liraglutide improved glycemic control and the quality of life scores in a case of type 2 diabetes and active Crohn's disease. 2014 , 53, 1637-40		1
497	Immunopathology of inflammatory bowel disease. 2014 , 20, 6-21		321
496	Tumor necrosis factor-alpha antagonists twenty years later: what do Cochrane reviews tell us?. 2014 , 20, 2132-41		12
495	Crohn's disease successfully treated with infliximab in a patient receiving hemodialysis: case report and review of the literature. 2014 , 93, e54		3
494	The 'either test positive' strategy for latent tuberculous infection before anti-tumour necrosis factor treatment. 2014 , 18, 428-34		21
493	Magnetic resonance elastography and transient elastography as non-invasive analyses for liver fibrosis: can they obviate the need for liver biopsy in psoriasis patients treated with methotrexate?. 2015 , 54, 752-6		34
492	The role of budesonide in the management of Crohn's disease. 2015 , 13, 26-33		
491	Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives. 2015 , 21, 21-46		108
490	Mycobacterium avium subspecies hominissuis in Crohn's disease: a case report. 2017 , 5, 316-319		2
489	Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety. 2015 , 55 Suppl 3, S60-74		31
488	Examining systemic steroid Use in older inflammatory bowel disease patients using hurdle models: a cohort study. 2015 , 16, 34		1
487	Use of Intravenous Immunoglobulin for Patients with Inflammatory Bowel Disease with Contraindications or Who Are Unresponsive to Conventional Treatments. 2015 , 21, 1854-9		16
486	Iatrogenic Cushing's syndrome related to the interaction between oral budesonide with fluvoxamine: a case report. 2015 , 40, 612-614		4
485	Clinical Practice Guideline for the Surgical Management of Crohn's Disease. 2015 , 58, 1021-36		78
484	Early Thiopurines Versus Conventional Step-Care Therapy for Modifying the Disease Course of Early Crohn's Disease: A Tertiary Referral Center Cohort Study. 2015 , 94, e1148		6
483	Endoscopy Assessment at 1-Year Identifies Long-Term Responders to Thiopurines Maintenance Therapy in Patients With Crohn's Disease. 2015 , 94, e1204		5
482	Body Image Dissatisfaction in Patients with Inflammatory Bowel Disease. 2015 , 21, 900		

481	Safety Profile of Thiopurines in Crohn Disease: Analysis of 893 Patient-Years Follow-Up in a Southern China Cohort. 2015 , 94, e1513	24
480	Does a personal or family history of malignancy preclude the use of immunomodulators and biologics in IBD. 2015 , 21, 428-35	9
479	Iron Replacement in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. 2015 , 21, 1976-81	10
478	High-Resolution Ultrasound Characterization of Colonic Lymphoid Hyperplasia in a Case of Active Crohn Colitis. 2015 , 31, e1-4	
477	Older age and steroid use are associated with increasing polypharmacy and potential medication interactions among patients with inflammatory bowel disease. 2015 , 21, 1392-400	33
476	Managing refractory Crohn's disease: challenges and solutions. <i>Clinical and Experimental Gastroenterology</i> , 2015 , 8, 131-40	3.1 5
475	A review of the impact of biologics on surgical complications in Crohn's disease. 2015 , 21, 1472-7	16
474	A Systematic Review of the Cost-Effectiveness of Biologics for the Treatment of Inflammatory Bowel Diseases. 2015 , 10, e0145087	30
473	Drug-induced liver injury from initial dose of infliximab. 2015 , 180, e723-4	5
472	Management of Musculoskeletal Manifestations in Inflammatory Bowel Disease. 2015 , 2015, 387891	13
471	Hereditary Angioedema and Gastrointestinal Complications: An Extensive Review of the Literature. 2015 , 2015, 925861	15
470	An Assessment of the AGA and CCFA Quality Indicators in a Sample of Patients Diagnosed with Inflammatory Bowel Disease. 2015 , 21, 1064-76	8
469	[Ideal vaccination strategy in inflammatory bowel disease]. 2015 , 65, 159-64	
468	Clinical and Sociodemographic Aspects of Inflammatory Bowel Disease Patients. 2015 , 8, 207-215	8
467	Current therapy of pediatric Crohn's disease. 2015 , 6, 33-42	18
466	Role of exclusive enteral nutrition in the preoperative optimization of patients with Crohn's disease following immunosuppressive therapy. 2015 , 94, e478	42
465	Sexual dysfunction in inflammatory bowel disease: "don't ask, don't tell" doesn't work. 2015 , 21, 948-50	5
464	Validation of gene expression biomarker analysis for biopsy-based clinical trials in Crohn's disease. 2015 , 21, 323-30	6

463	The Value of Vedolizumab as Rescue Therapy in Moderate-Severe Crohn's Disease Patients with Adalimumab Non-response in the USA. <i>Journal of Crohns and Colitis</i> , 2015 , 9, 669-75	1.5	10
462	Challenges in the Diagnosis and Management of Inflammatory Bowel Disease in the Elderly. 2015 , 13, 275-86		15
461	Overview of Medical Management of Crohn's Disease. 2015 , 163-171		
460	Definition of Prostaglandin E2-EP2 Signals in the Colon Tumor Microenvironment That Amplify Inflammation and Tumor Growth. 2015 , 75, 2822-32		84
459	Tripterygium wilfordii Hook F as Maintenance Treatment for Crohn's Disease. 2015 , 350, 345-51		25
458	Vedolizumab: An integrin-receptor antagonist for treatment of Crohn's disease and ulcerative colitis. 2015 , 72, 1271-8		6
457	Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. 2015 , 14, 1915-34		3
456	Drug resistance in inflammatory bowel diseases. 2015 , 25, 56-61		12
455	Tripterygium wilfordii Hook. f. versus azathioprine for prevention of postoperative recurrence in patients with Crohn's disease: a randomized clinical trial. 2015 , 47, 14-9		29
454	An update on medical management on Crohn's disease. 2015 , 16, 63-78		7
453	Gastrointestinal disorders. 2015 , 1-16		
452	Prevalence of chronic narcotic use among children with inflammatory bowel disease. 2015 , 13, 310-315.e2		19
451	Review article: the safety of therapeutic drugs in male inflammatory bowel disease patients wishing to conceive. 2015 , 41, 821-34		47
450	Clinical effectiveness and cost-effectiveness of elemental nutrition for the maintenance of remission in Crohn's disease: a systematic review and meta-analysis. 2015 , 19, 1-138		1842
449	If variety is the spice of life, we need to rethink our recipe: variation in inflammatory bowel disease practice among tertiary centers. 2015 , 13, 1201-3		1
448	The impact of a ten-week physical exercise program on health-related quality of life in patients with inflammatory bowel disease: a prospective randomized controlled trial. 2015 , 91, 239-47		110
447	Cutaneous Manifestations of Crohn Disease. 2015 , 33, 417-31		43
446	Colon Polyps and the Prevention of Colorectal Cancer. 2015 ,		1

445	Characterization of de novo colonic stricture due to Crohn's disease. 2014 , 25 Suppl 1, 129-32		
444	Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease. 2015 , 9, 497-505		13
443	Inflammatory bowel disease and the elderly: a review. <i>Journal of Crohns and Colitis</i> , 2015 , 9, 507-15	1.5	82
442	Patients with Crohn's Disease Are More Likely to Remain on Biologics than Immunomodulators: A Meta-Analysis of Treatment Durability. 2015 , 60, 2408-18		5
441	5-Aminosalicylic acid, a specific drug for ulcerative colitis. 2015 , 50, 933-41		38
440	Inflammatory Bowel Disease. 2015 ,		0
439	Clinical, biological, and endoscopic responses to adalimumab in antitumor necrosis factor-naïve Crohn's disease: predictors of efficacy in clinical practice. 2015 , 27, 430-5		13
438	Testing for Clostridium difficile in patients newly diagnosed with inflammatory bowel disease in a community setting. 2015 , 21, 564-9		9
437	Frequency and Appropriateness of Fasting Orders in the Hospital. 2015 , 90, 1225-32		20
436	Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma--challenges in management. 2015 , 30, 1595-602		2
435	Variations in care: a retrospective database analysis of healthcare utilization patterns for patients with inflammatory bowel disease. 2015 , 18, 137-44		5
434	Idiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: retrospective analysis of 9095 patients. 2015 , 41, 99-107		8
433	Thyroid disorders and gastrointestinal and liver dysfunction: A state of the art review. 2015 , 26, 563-71		28
432	Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease. 2015 , 41, 1079-93		28
431	Biologic agents for IBD: practical insights. 2015 , 12, 537-45		196
430	Primary Care of the Patient with Inflammatory Bowel Disease. 2015 , 99, 969-87		5
429	Cost-effectiveness of Prophylaxis Against Pneumocystis jiroveci Pneumonia in Patients with Crohn's Disease. 2015 , 60, 3743-55		12
428	Quantitative assessment of CD30+ lymphocytes and eosinophils for the histopathological differential diagnosis of inflammatory bowel disease. <i>Journal of Crohns and Colitis</i> , 2015 , 9, 763-8	1.5	7

427	From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease. 2015 , 8, 143-59	21
426	Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's disease. 2015 , 1, e000097	78
425	Conventional drug therapy for inflammatory bowel disease. 2015 , 50, 90-112	44
424	Crohn's Disease. 2015 ,	1
423	Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. 2015 , 148, 37-51.e1	162
422	The role and advances of immunomodulator therapy for inflammatory bowel disease. 2015 , 9, 177-89	22
421	Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases. 2015 , 165, 270-82	87
420	Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study. 2016 , 57, 1376-85	15
419	Diet and nutritional factors in inflammatory bowel diseases. 2016 , 22, 895-905	118
418	Role of antibiotics for treatment of inflammatory bowel disease. 2016 , 22, 1078-87	122
417	Adjunctive Hyperbaric Oxygen Therapy promotes successful healing in patients with refractory Crohn's disease. 2016 , 31 Suppl 1, 19-23	14
416	Phase III Placebo-Controlled, Randomized Clinical Trial With Synthetic Crohn's Disease Patients to Evaluate Treatment Response. 2016 , 411-427	5
415	Advances in nutritional therapy in inflammatory bowel diseases: Review. 2016 , 22, 1045-66	62
414	Elderly patients and inflammatory bowel disease. 2016 , 7, 51-65	36
413	Magnetic Resonance Imaging of the Small Bowel in Crohn's Disease: A Systematic Review and Meta-Analysis. 2016 , 2016, 7857352	12
412	Thiopurines in the Management of Crohn's Disease: Safety and Efficacy Profile in Patients with Normal TPMT Activity-A Retrospective Study. 2016 , 2016, 1034834	12
411	Management of Inflammatory Bowel Disease Using Stem Cell Therapy. 2016 , 11, 72-7	14
410	The Same Intestinal Inflammatory Disease despite Different Genetic Risk Factors in the East and West?. 2016 , 1, 78-84	2

409	Prevalence of Upper Gastrointestinal Lesions at Primary Diagnosis in Adults with Inflammatory Bowel Disease. 2016 , 22, 1896-901	62
408	Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia, and Mexico. 2016 , 19, 1187-1199	4
407	Clostridium difficile Infection in Inflammatory Bowel Disease: A Nursing-Based Quality Improvement Strategy. 2016 , 38, 283-9	6
406	Medication Utilization and the Impact of Continued Corticosteroid Use on Patient-reported Outcomes in Older Patients with Inflammatory Bowel Disease. 2016 , 22, 1435-41	20
405	Management of Inflammatory Bowel Disease in the Elderly. 2016 , 14, 285-304	19
404	Macrophages Versus Escherichia coli: A Decisive Fight in Crohn's Disease. 2016 , 22, 2943-2955	4
403	The role of mesenchymal stromal cells in the treatment of ulcerative colitis and Crohn's disease. 2016 , 730-753	
402	Inflammatory Bowel Disease: Epidemiology, Evaluation, Treatment, and Health Maintenance. 2016 , 77, 198-201	6
401	Gastrointestinal diseases and their oro-dental manifestations: Part 1: Crohn's disease. 2016 , 221, 794-799	20
400	Ulcerative Colitis. 2016 , 323-327	
399	Crohn's Disease. 2016 , 273-278	
398	RDW as a Surrogate Marker for Active Crohn's Disease: Potential Utility. 2016 , 23, 1-3	1
397	Primary Care Evaluation and Management of Gastroenterologic Issues in Women. 2016 , 43, 347-66	2
396	Budesonide for the treatment of ulcerative colitis. 2016 , 17, 1549-59	23
395	P-098 Serious Infections in Patients Treated with Certolizumab Pegol with or Without Corticosteroids. 2016 , 22, S40	
394	Opportunities for Improvement in the Care of Patients Hospitalized for Inflammatory Bowel Disease-Related Colitis. 2016 , 61, 1003-12	16
393	Current challenges in the surgical management of Crohn's disease: a systematic review. 2016 , 212, 345-51	25
392	Medical Management of Crohn's Disease. 2016 , 807-817	

391	Inflammatory bowel diseases and reproductive health. 2016 , 68, 859-64		4
390	Therapeutic challenges of managing inflammatory bowel disease in the elderly patient. 2016 , 10, 1005-10		4
389	Inflicting Confusion. 2016 , 104, 90-54		
388	Inflammation chronique de l'intestin et rhumatismes inflammatoires (maladie de Crohn, RCH, maladie de Behçet) : prise en charge thérapeutique. 2016 , 83, 207-212		1
387	Steroid dependency and trends in prescribing for inflammatory bowel disease - a 20-year national population-based study. 2016 , 44, 482-94		32
386	A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1599-1607	0.7	214
385	Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases. 2016 , 43 Suppl 1, 27-36		39
384	Crohn's Disease: Specific Concerns in the Elderly. 2016 , 10, 126-130		3
383	Approach to the Patient with Mild Crohn's Disease: a 2016 Update. 2016 , 18, 50		4
382	Immune Based Therapies for Inflammatory Bowel Disease. 2016 , 37-61		
381	Prediction of low bone mineral density in patients with inflammatory bowel diseases. 2016 , 4, 669-676		18
380	Therapeutic modulation of gut microbiota in inflammatory bowel disease: More questions to be answered. 2016 , 17, 800-810		26
379	Does a Higher Prevalence for Primary Diagnosis of Crohn's Disease Involve the Upper Gastrointestinal Tract?. 2016 , 22, E32-3		
378	Prevalence of Upper Gastrointestinal Lesions at Primary Diagnosis in Adults with Inflammatory Bowel Disease. 2016 , 22, E33-4		3
377	Practice Variations in the Management of Inflammatory Bowel Disease Between Pediatric and Adult Gastroenterologists. 2016 , 62, 372-7		9
376	Food, nutrients and nutraceuticals affecting the course of inflammatory bowel disease. 2016 , 68, 816-26		88
375	Coexistence of Multiple Ileal Neuroendocrine Tumors and Idiopathic Myointimal Hyperplasia of Mesenteric Veins: Coincidence or Consequence? Case Report and Review of Literature. 2016 , 24, 627-30		7
374	Crohn's disease: is there any link between anal and luminal phenotypes?. 2016 , 31, 307-11		3

373	Vedolizumab in moderately to severely active ulcerative colitis or Crohn's disease: a guide to its use. 2016 , 32, 265-275	1
372	Bowel Ultrasonography in the Management of Crohn's Disease. A Review with Recommendations of an International Panel of Experts. 2016 , 22, 1168-83	89
371	The role of specialty pharmacy drugs in the management of inflammatory diseases. 2016 , 73, 821-30	8
370	Is there a role for prophylactic colectomy in Lynch syndrome patients with inflammatory bowel disease?. 2016 , 31, 9-13	7
369	MR enterography-histology comparison in resected pediatric small bowel Crohn disease strictures: can imaging predict fibrosis?. 2016 , 46, 498-507	51
368	What's Next for Gastrointestinal Disorders: No Needles?. 2016 , 221, 48-61	4
367	Effectiveness of anti-TNF drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNF agent. 2016 , 48, 613-9	9
366	DWI at MR Enterography for Evaluating Bowel Inflammation in Crohn Disease. 2016 , 207, 40-8	40
365	Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases. 2016 , 22, 224-33	71
364	Asia Pacific Consensus Statements on Crohn's disease. Part 1: Definition, diagnosis, and epidemiology: (Asia Pacific Crohn's Disease Consensus--Part 1). 2016 , 31, 45-55	70
363	Endoscopic Complete Remission of Crohn Disease After Anti-Tumor Necrosis Factor- α Therapy: CT Enterographic Findings and Their Clinical Implications. 2016 , 206, 1208-16	13
362	Anal Fistula in Crohn's Disease. 2016 , 115-126	
361	Biosimilars: Rationale and current regulatory landscape. 2016 , 45, S1-10	36
360	Vedolizumab in the treatment of Crohn's disease. 2016 , 10, 283-90	9
359	JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. 2016 , 310, G155-62	100
358	Discrimination of inflammatory bowel disease using Raman spectroscopy and linear discriminant analysis methods. 2016 ,	2
357	The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease. 2016 , 61, 589-96	11
356	Timing of Thiopurine or Anti-TNF Initiation Is Associated with the Risk of Major Abdominal Surgery in Crohn's Disease: A Retrospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2016 , 10, 55-60	1.5 20

355	Quantitative Contrast-Enhanced Ultrasound Parameters in Crohn Disease: Their Role in Disease Activity Determination With Ultrasound. 2016 , 206, 64-73	45
354	Surgical Emergencies in Crohn Disease. 2016 , 153-157	1
353	Telemanagement of Inflammatory Bowel Disease. 2016 ,	2
352	Colectomy with Permanent End Ileostomy Is More Cost-Effective than Ileal Pouch-Anal Anastomosis for Crohn's Colitis. 2016 , 61, 550-9	11
351	Health Insurance Paid Costs and Drivers of Costs for Patients With Crohn's Disease in the United States. <i>American Journal of Gastroenterology</i> , 2016 , 111, 15-23	0.7 55
350	Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. 2016 , 14, 348-354.e17	17
349	Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease. 2016 , 55, 257-74	35
348	Vedolizumab: A New Opponent in the Battle Against Crohn's Disease and Ulcerative Colitis. 2016 , 29, 503-15	4
347	Pulmonary Crohn's Disease. 2017 , 62, 64-67	1
346	Considerations in Imaging Among Emergency Department Patients With Inflammatory Bowel Disease. 2017 , 69, 587-599	12
345	An evaluation of health care expenditures in Crohn's disease using the United States Medical Expenditure Panel Survey from 2003 to 2013. 2017 , 13, 530-538	19
344	Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence. 2017 , 10, 391-400	4
343	Costs of providing infusion therapy for patients with inflammatory bowel disease in a hospital-based infusion center setting. 2017 , 20, 409-422	6
342	Clinical Practice Guidelines for the Use of Video Capsule Endoscopy. 2017 , 152, 497-514	213
341	Crohn's disease diagnosis, treatment approach, and management paradigm: what the radiologist needs to know. 2017 , 42, 1068-1086	15
340	Intestinal Inflammation Does Not Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients. 2017 , 62, 1354-1361	20
339	Dietary treatment of Crohn's disease: perceptions of families with children treated by exclusive enteral nutrition, a questionnaire survey. 2017 , 17, 14	19
338	Factors associated with pregnancy-related knowledge in women of reproductive age with inflammatory bowel disease. 2017 , 52, 833-839	5

337	Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis. 2017 , 23, 461-472	33
336	Understanding the Gut Microbiota in Inflammatory and Functional Gastrointestinal Diseases. 2017 , 79, 857-867	31
335	Patient Understanding of the Risks and Benefits of Biologic Therapies in Inflammatory Bowel Disease: Insights from a Large-scale Analysis of Social Media Platforms. 2017 , 23, 1057-1064	29
334	Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities. 2017 , 23, 882-893	44
333	Biologic Therapy for Crohn's Disease: Infliximab. 2017 , 357-365	
332	Is Mesalamine Effective for the Induction of Remission in Crohn's Disease?. 2017 , 23, E22-E23	2
331	Special situations in inflammatory bowel disease: First Latin American consensus of the Pan American Crohn's and Colitis Organisation (PANCCO) (Second part). 2017 , 82, 134-155	
330	Step-Up vs. Top-Down Approach in Crohn's Disease. 2017 , 481-489	
329	Development of a Novel Predictive Model for the Clinical Course of Crohn's Disease: Results from the CONNECT Study. 2017 , 23, 1071-1079	18
328	MRI features of perianal fistulas: is there a difference between Crohn's and non-Crohn's patients?. 2017 , 42, 1162-1168	7
327	How should we treat mild and moderate-severe Crohn's disease in 2017? A brief overview of available therapies. 2017 , 11, 95-97	
326	Dysplasia and Cancer in Inflammatory Bowel Disease. 2017 , 97, 627-639	17
325	Crohn Disease: Epidemiology, Diagnosis, and Management. 2017 , 92, 1088-1103	161
324	Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease. 2017 , 23, 1210-1217	16
323	Laparoscopic Intervention in Acute Crohn's Disease Involving an Ovary. 2017 , 24, 1040-1045	3
322	Fecal microbiota transplantation for gastrointestinal disorders. 2017 , 33, 8-13	22
321	Postoperative prophylaxis in Crohn's disease after intestinal resection: a retrospective analysis. 2017 , 8, 203-209	6
320	Eldelumab [anti-interferon- γ inducible protein-10 antibody] Induction Therapy for Active Crohn's Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 811-819	1.5 19

319	Is there a role of magnetic resonance imaging in deciding to stop anti-tumor necrosis factor treatment in ileal Crohn's disease?. 2017 , 43, 175-179	4
318	Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis. 2017 , 23, 570-577	58
317	SICUS and CEUS imaging in Crohn's disease: an update. 2017 , 20, 1-9	23
316	Special situations in inflammatory bowel disease: First Latin American consensus of the Pan American Crohn's and Colitis Organisation (PANCCO) (Second part). 2017 , 82, 134-155	2
315	Real-world Experience of Anti-tumor Necrosis Factor Therapy for Internal Fistulas in Crohn's Disease: A Retrospective Multicenter Cohort Study. 2017 , 23, 2245-2251	10
314	Inflammatory Bowel Disease: Predictors and Causes of Early and Late Hospital Readmissions. 2017 , 23, 1832-1839	19
313	Cost of Illness in Inflammatory Bowel Disease. 2017 , 62, 2318-2326	15
312	Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. 2017 , 23, 97-106	110
311	Extraintestinal Manifestations Are Common in Obese Patients with Crohn's Disease. 2017 , 23, 1637-1642	11
310	Optimizing Inflammatory Bowel Disease Management: An Overview for the Gastroenterology Nurse. 2017 , 40 Suppl 1S, S1-S14	
309	Reply. 2017 , 23, E23-E24	
308	Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis: Republished. 2017 , 23, E26-E37	7
307	Risk of Malignancy in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients. 2017 , 34, 859-868	23
306	Glucocorticoids. 2017 , 1467-1484	
305	An Update on Inflammatory Bowel Disease. 2017 , 44, 673-692	193
304	Getting the best out of biological and biosimilar medicines for inflammatory bowel disease. 2017 , 15, 16-23	3
303	Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study. 2017 , 96, e6788	18
302	Inflammatory Bowel Disease. 2017 ,	2

301	Does Metabolic Syndrome and Not the Inflammatory Load Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients?. 2017 , 62, 2604-2606	2
300	Multiple fresh fecal microbiota transplants induces and maintains clinical remission in Crohn's disease complicated with inflammatory mass. 2017 , 7, 4753	54
299	Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. 2017 , 46, 389-400	206
298	Nutrition Matters in IBD. 2017 , 233-255	
297	Comparison of Endoscopic Dilatation vs Surgery for Anastomotic Stricture in Patients With Crohn's Disease Following Ileocolonic Resection. 2017 , 15, 1226-1231	42
296	Specifics and Pitfalls in Diagnosis of Inflammatory Bowel Diseases. 2017 , 347-354	
295	Chromoendoscopy for Surveillance in Ulcerative Colitis and Crohn's Disease: A Systematic Review of Randomized Trials. 2017 , 15, 1684-1697.e11	48
294	Complementary and Alternative Medicine Strategies for Therapeutic Gut Microbiota Modulation in Inflammatory Bowel Disease and their Next-Generation Approaches. 2017 , 46, 689-729	18
293	Perioperative use of immunosuppressive medications in patients with Crohn's disease in the new "biological era". 2017 , 5, 165-177	22
292	Symptomatic Microscopic Colitis Atop Quiescent Inflammatory Bowel Disease: A Case Series. 2017 , 4, e124	3
291	Clinical characterization of inflammatory bowel disease with Raman spectroscopy. 2017 , 8, 524-535	31
290	Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease. 2017 , 15, 285-310	22
289	Impact of biological therapy on body composition of patients with Chron's disease. 2017 , 63, 407-413	10
288	The Impact of Western Diet and Nutrients on the Microbiota and Immune Response at Mucosal Interfaces. 2017 , 8, 838	196
287	Second Korean guidelines for the management of Crohn's disease. 2017 , 15, 38-67	28
286	Diffusion-Weighted MR Enterography to Monitor Bowel Inflammation after Medical Therapy in Crohn's Disease: A Prospective Longitudinal Study. 2017 , 18, 162-172	23
285	Efficacy and Safety of Oral Budesonide in Patients with Active Crohn's Disease in Japan: A Multicenter, Double-Blind, Randomized, Parallel-Group Phase 3 Study. 2018 , 2, 154-162	9
284	Rates of hospitalization among African American and Caucasian American patients with Crohn's disease seen at a tertiary care center. 2017 , 5, 288-292	6

283	Patient experience with intravenous biologic therapies for ankylosing spondylitis, Crohn's disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, and ulcerative colitis. 2017 , 11, 661-669	18
282	[Second Korean Guidelines for the Management of Crohn's Disease]. 2017 , 69, 29-54	9
281	Muscle function and quality of life in the Crohn's disease. 2017 , 30, 337-345	4
280	Inflammatory bowel disease: An evaluation of health information on the internet. 2017 , 23, 1676-1696	26
279	Video assisted patient education improves compliance with follow up and depression scores in Inflammatory Bowel Diseases. 2018 , 130, 355-360	5
278	Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience. 2018 , 24, 490-501	53
277	Outcomes of Endoscopic Balloon Dilation vs Surgical Resection for Primary Ileocolic Strictures in Patients With Crohn's Disease. 2018 , 16, 1260-1267	20
276	Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study. 2018 , 67, 1824-1835	64
275	Using insurance claims to predict and improve hospitalizations and biologics use in members with inflammatory bowel diseases. 2018 , 81, 93-101	1
274	Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti- α 4 integrin therapy for inflammatory bowel disease. 2018 , 47, 1440-1452	19
273	A Refractory Cutaneous Abscess. 2018 , 131, e259-e260	
272	Enteropathy in Psoriasis: A Systematic Review of Gastrointestinal Disease Epidemiology and Subclinical Inflammatory and Functional Gut Alterations. 2018 , 7, 59-74	4
271	Efficacy of Medical Therapies for Fistulizing Crohn's Disease: Systematic Review and Meta-analysis. 2018 , 16, 1879-1892	70
270	Long-term Outcome of Early Combined Immunosuppression Versus Conventional Management in Newly Diagnosed Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 517-524	1.5 21
269	Evidence-based clinical practice guidelines for inflammatory bowel disease. 2018 , 53, 305-353	249
268	Immunogenicity of biologics in inflammatory bowel disease. 2018 , 11, 1756283X17750355	110
267	Mortality Is Rare Following Elective and Non-elective Surgery for Ulcerative Colitis, but Mild Postoperative Complications Are Common. 2018 , 63, 713-722	7
266	Biologic-Induced Infections in Inflammatory Bowel Disease: The TNF- α Antagonists. 2018 , 52, 571-579	8

265	Factors That Contribute to Indeterminate Results From the QuantiFERON-TB Gold In-Tube Test in Patients With Inflammatory Bowel Disease. 2018 , 16, 1616-1621.e1		10
264	Serum amyloid A level correlated with endoscopic findings in patients with Crohn's disease-Possible biomarker for evaluating mucosal healing. 2018 , 50, 553-558		9
263	Listeria Monocytogenes Brain Abscess in Crohn's Disease Treated with Adalimumab. 2017 , 11, 667-671		5
262	Daily hassles score associates with the somatic and psychological health of patients with Crohn's disease. 2018 , 74, 969-988		9
261	Editorial: avoiding corticosteroids in the treatment of inflammatory bowel disease. 2018 , 47, 143-144		0
260	Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era-Results from the Dutch Population-Based IBDSL Cohort. <i>American Journal of Gastroenterology</i> , 2018 , 113, 384-395	0.7	8
259	A Role for Thiopurine Metabolites in the Synergism Between Thiopurines and Infliximab in Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , 2018 , 12, 298-305	1.5	14
258	Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy. 2018 , 24, 2272-2277		7
257	Management of Crohn's Disease and Complications in Patients With Ostomies. 2018 , 24, 1167-1184		6
256	Letter: predicting azathioprine-associated pancreatitis in IBD-phenotype or genotype? Authors' reply. 2018 , 47, 1044-1045		
255	Differing Relationship of Psycho-Social Variables with Active Ulcerative Colitis or Crohn's Disease. 2018 , 25, 341-350		10
254	Methotrexate Pneumonitis in Crohn's Disease: A Rare Case Report and Review of Literature. 2018 , 54, 535-536		0
253	ACG Clinical Guideline: Management of Crohn's Disease in Adults. <i>American Journal of Gastroenterology</i> , 2018 , 113, 481-517	0.7	518
252	Variations in the medical treatment of inflammatory bowel disease among gastroenterologists. 2018 , 6, 61-64		9
251	Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. 2018 , 24, 849-860		24
250	Socioeconomic Status and Race are both Independently associated with Increased Hospitalization Rate among Crohn's Disease Patients. 2018 , 8, 4028		6
249	Donkey milk consumption exerts anti-inflammatory properties by normalizing antimicrobial peptides levels in Paneth's cells in a model of ileitis in mice. 2018 , 57, 155-166		28
248	Development of an index to define overall disease severity in IBD. 2018 , 67, 244-254		73

247	Non-Clostridium difficile Bacterial Infections Are Rare in Patients With Flares of Inflammatory Bowel Disease. 2018 , 16, 528-533	17
246	Association between chronic immune-mediated inflammatory diseases and cardiovascular risk. 2018 , 104, 119-126	37
245	A comprehensive review and update on Crohn's disease. 2018 , 64, 20-57	163
244	Inflammatory Bowel Disease. 2018 , 501-516.e8	4
243	Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis. <i>American Journal of Gastroenterology</i> , 2018 , 113, 58-71	0.7 27
242	Antitumor Necrosis Factor Agents in Ulcerative Colitis. 2018 , 13-32	
241	Quality of care in inflammatory bowel diseases: What is the best way to better outcomes?. 2018 , 24, 2363-2372	13
240	Inflammatory bowel disease: cost-driving factors and impact of cost sharing on outpatient resource utilization. 2018 , 9, 301-307	1
239	Precision Medicine Versus Population Medicine in Colon Cancer: From Prospects of Prevention, Adjuvant Chemotherapy, and Surveillance. 2018 , 38, 220-230	7
238	Causative Agents of Drug-Induced Pancreatitis: A Nationwide Assessment. 2018 , 47, 1328-1336	7
237	Crohn's Disease Treatment Expenditures over Fifteen Years of Follow-Up. 2018 , 03,	
236	Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting. 2018 , 9, 8-13	2
235	Impaired Coagulation Status in the Crohn's Disease Patients Complicated with Intestinal Fistula. 2018 , 131, 567-573	0
234	Intestinal Anti-Inflammatory Activity of the Aqueous Extract from Ipomoea asarifolia in DNBS-Induced Colitis in Rats. 2018 , 19,	18
233	Screening and surveillance methods for dysplasia in inflammatory bowel disease patients: Where do we stand?. 2018 , 10, 250-258	6
232	Methotrexate Pneumonitis in Crohn's Disease: A Rare Case Report and Review of Literature. 2018 , 54, 535-536	1
231	Evaluation of a new pan-enteric video capsule endoscopy system in patients with suspected or established inflammatory bowel disease - feasibility study. 2018 , 6, E1235-E1246	28
230	Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting. 2018 , 24, 2431-2441	52

229	Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn's disease?. <i>Annals of Gastroenterology</i> , 2018 , 31, 413-424	2.2	18
228	Preparation and characterization of pH-sensitive nanoparticles of budesonide for the treatment of ulcerative colitis. 2018 , 12, 2601-2609		19
227	Sweet Olive Extract Attenuates Dextran Sulfate Sodium-Induced Colitis in Mice. 2018 , 21, 1244-1252		4
226	Infliximab-Induced Aseptic Meningitis in a Patient with Crohn's Disease. 2018 , 5, e48		4
225	Treatment of Inflammatory Bowel Disease in the Older Patient. 2018 , 24, 1155-1166		5
224	Clinical Benefit of Capsule Endoscopy in Crohn's Disease: Impact on Patient Management and Prevalence of Proximal Small Bowel Involvement. 2018 , 24, 1582-1588		20
223	Adult Inflammatory Bowel Disease, Physical Rehabilitation, and Structured Exercise. 2018 , 24, 2543-2549		6
222	Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease. 2018 , 48, 114-126		7
221	Endoscopic Treatment of Bezoars and Foreign Bodies in Patients With Inflammatory Bowel Disease. 2018 , 309-317		1
220	Inflammatory Bowel Disease. 2018 , 230-233		
219	Enteral Nutrition in the Management of Pediatric and Adult Crohn's Disease. 2018 , 10,		25
218	Reviewing the therapeutic role of budesonide in Crohn's disease. 2018 , 41, 458-471		2
217	[Evolving Therapeutic Strategies in the Inflammatory Bowel Disease]. 2018 , 71, 61-68		3
216	Natalizumab for induction of remission in Crohn's disease. 2018 , 8, CD006097		21
215	Anti-microbial Antibodies, Host Immunity, and Autoimmune Disease. 2018 , 5, 153		11
214	Magnetic Resonance Enterography for Inflammatory and Noninflammatory Conditions of the Small Bowel. 2018 , 56, 671-689		7
213	Physicians' Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohn's Disease. 2018 , 63, 2555-2563		6
212	Efficacy of restarting anti-tumor necrosis factor agents after surgery in patients with Crohn's disease. 2018 , 16, 75-82		5

211	Reviewing the therapeutic role of budesonide in Crohn's disease. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018 , 41, 458-471	0.1	1
210	Exploring the associations between systemic inflammation, obesity and healthy days: a health related quality of life (HRQOL) analysis of NHANES 2005-2008. 2018 , 5, 21		11
209	Biologics and biosimilars in inflammatory bowel disease. 2018 , 16, 14-18		
208	Magnetic resonance enterography predicts the prognosis of Crohn's disease. 2018 , 16, 445-457		6
207	Intravenous catheters induce a local inflammatory response. 2018 , 111, 470-474		3
206	Prediction of disease activity of Crohn's disease through fecal calprotectin evaluated by balloon-assisted endoscopy. 2018 , 33, 1984-1989		10
205	Meta-Analysis: The Influence of Preoperative Infliximab Use on Postoperative Complications of Crohn's Disease. 2019 , 25, 261-269		23
204	Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review. 2019 , 25, 1142-1157		42
203	From clinical practice guideline development to trial registration: A systematic investigation of research pipeline for inflammatory bowel disease. 2019 , 38, 247-262		
202	Hepatic Complications of Inflammatory Bowel Disease. 2019 , 23, 191-208		11
201	Medical Management of Inflammatory Bowel Disease. 2019 , 99, 1223-1235		5
200	Small bowel stricture is associated with abnormal motility on the cine MRI sequence in patients with Crohn's disease. 2019 , 118, 264-270		5
199	Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data. 2019 , 36, 3079-3095		9
198	Imaging in discriminating intestinal tuberculosis and Crohn's disease: past, present and the future. 2019 , 13, 995-1007		14
197	Healthcare Providers Underestimate Patients' Glucocorticoid Use in Crohn's Disease. 2019 , 64, 1142-1149		4
196	Gastrointestinal Tract Disorders in Older Age. 2019 , 2019, 6757524		70
195	Regional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases. 2019 , 34, 1166-1174		10
194	Strictures in Crohn's Disease and Ulcerative Colitis: Is There a Role for the Gastroenterologist or Do We Always Need a Surgeon?. 2019 , 29, 549-562		1

193	Crohn's Disease: Potential Drugs for Modulation of Autophagy. 2019 , 55,	3
192	A Comprehensive Review of the Diagnosis and Pharmacological Management of Crohn's Disease in the Elderly Population. 2019 , 36, 607-624	3
191	Imaging Features Associated With Failure of Nonoperative Management of Intraabdominal Abscesses in Crohn Disease. 2019 , 25, 1939-1944	5
190	The Synergistic Role of Diet and Exercise in the Prevention, Pathogenesis, and Management of Ulcerative Colitis: An Underlying Metabolic Mechanism. 2019 , 12, 1178638819834526	4
189	Functional Cross-Sectional Imaging Techniques in Crohn's Disease. 2019 , 93-123	
188	Short-Term Outcomes of Inflammatory Bowel Disease after Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy. 2019 , 228, 893-901.e1	12
187	Adalimumab-induced acute myeloid leukaemia in a patient with Crohn's disease. 2019 , 12,	1
186	Dietary Interventions and Inflammatory Bowel Disease. 2019 , 33-42	
185	Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease. 2019 , 25, 1357-1366	3
184	Paraoxonase-1 and arylesterase levels in patients with ulcerative colitis. 2019 , 20, 14-18	1
183	Experiencing the care of a family member with Crohn's disease: a qualitative study. 2019 , 9, e030625	2
182	Simplification of Validated Patient-Reported Outcome Instruments in Inflammatory Bowel Disease. 2019 , 1,	
181	Changes in the Management of Patients with Crohn's Disease Based on Magnetic Resonance Enterography Patterns. 2019 , 2019, 3467316	3
180	Adalimumab for induction of remission in Crohn's disease. 2019 , 2019,	4
179	Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system. 2019 , 14, e0225572	8
178	What every PA needs to know about anorectal pain. 2019 , 32, 1-7	0
177	Effect of Oral Nutrition Supplements and TGF- β on Nutrition and Inflammatory Patterns in Patients With Active Crohn's Disease. 2020 , 35, 885-893	4
176	Serum Protein Biomarkers of Fibrosis Aid in Risk Stratification of Future Stricture Complications in Pediatric Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2019 , 114, 777-785	0.7 15

175	Traditional Chinese medicine for management of recurrent and refractory Crohn disease: A case report. 2019 , 98, e15148		3
174	Inflammatory bowel disease during pregnancy: management of a disease flare or remission. 2019 , 35, 281-287		4
173	<i>Bacteroides thetaiotaomicron</i> Ameliorates Colon Inflammation in Preclinical Models of Crohn's Disease. 2019 , 25, 85-96		62
172	Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients. 2019 , 39, 118-128		4
171	Augmented Endoscopy for Surveillance of Colonic Inflammatory Bowel Disease: Systematic Review With Network Meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, 714-724	1.5	16
170	Evaluation of CT enterography findings for endoscopic complete remission after anti-TNF- α therapy in patients with Crohn's disease. 2019 , 60, 1200-1208		0
169	An Increased Abundance of Clostridiaceae Characterizes Arthritis in Inflammatory Bowel Disease and Rheumatoid Arthritis: A Cross-sectional Study. 2019 , 25, 902-913		31
168	Exclusive enteral nutrition in Crohn's disease: Evidence and practicalities. 2019 , 38, 80-89		53
167	The Impact of Spirituality and Religiosity on Mental Health and Quality of Life of Patients with Active Crohn's Disease. 2020 , 59, 1273-1286		3
166	Assessment of bioelectrical phase angle as a predictor of nutritional status in patients with Crohn's disease: A cross sectional study. 2020 , 39, 1564-1571		17
165	Plumericin prevents intestinal inflammation and oxidative stress in vitro and in vivo. 2020 , 34, 1576-1590		17
164	Is there room for immunomodulators in ulcerative colitis?. 2020 , 20, 379-390		2
163	Long-term deep remission during maintenance therapy with biological agents in inflammatory bowel diseases. 2020 , 55, 34-40		5
162	Identifying dimensions of empowerment in patients with inflammatory bowel disease: a qualitative study. 2020 , 35, 637-647		1
161	Risk of Uveitis in Patients With Inflammatory Bowel Disease on Immunosuppressive Drug Therapy. 2020 , 2,		2
160	Challenges in the Management of Inflammatory Bowel Disease. 2020 , 1-16		1
159	Network meta-regression for ordinal outcomes: Applications in comparing Crohn's disease treatments. 2020 , 39, 1846		1
158	Acid-resistant ROS-responsive hyperbranched polythioether micelles for ulcerative colitis therapy. 2020 , 31, 3102-3106		13

157	Systematic Review of Development and Content Validity of Patient-reported Outcome Measures in Inflammatory Bowel Disease: Do We Measure What We Measure?. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 1299-1315	1.5	8
156	Management of the Elderly Inflammatory Bowel Disease Patient. 2020 , 101 Suppl 1, 105-119		11
155	Imaging Findings of Ileal Inflammation at Computed Tomography and Magnetic Resonance Enterography: What do They Mean When Ileoscopy and Biopsy are Negative?. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 455-464	1.5	7
154	Exploratory clinical characterization of experimentally-induced ulcerative colitis nonhuman primates. 2020 , 6, e03178		1
153	Quantitative Inflammation Assessment for Crohn Disease Using Ultrasensitive Ultrasound Microvessel Imaging: A Pilot Study. 2020 , 39, 1819-1827		2
152	Mucosal healing in Crohn's disease: new insights. 2020 , 14, 335-345		8
151	A review of hematopoietic stem cell transplantation for autoimmune diseases: multiple sclerosis, systemic sclerosis and Crohn's disease. Position paper of the Brazilian Society of Bone Marrow Transplantation. 2021 , 43, 65-86		7
150	Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. 2021 , 27, 106-122		6
149	Risk factors for urolithiasis in patients with Crohn's disease. 2021 , 28, 220-224		
148	Normative data for the Brief Symptom Inventory for patients with Crohn's disease. 2021 , 1-12		1
147	Pharmacology of Aging. 2021 , 249-277		
146	Therapeutic targets and potential agents for the treatment of COVID-19. 2021 , 41, 1775-1797		11
145	Challenges in the Management of Inflammatory Bowel Disease. 2021 , 1675-1690		
144	Detection of mutations in gene in Arab patients with Crohn's disease. 2021 , 27, 240-248		0
143	Trends in US emergency department visits and subsequent hospital admission among patients with inflammatory bowel disease presenting with abdominal pain: a real-world study from a national emergency department sample database. 2021 , 9, 1912924		
142	Evaluation of the modified Crohn's disease activity index in patients with Crohn disease with enterostomy: A single-center observational study. 2021 , 100, e24717		0
141	Gummatous cutaneous tuberculosis associated with the use of infliximab for Crohn's disease. 2021 , 96, 228-230		0
140	Natural History and Risk Stratification of Recurrent Crohn's Disease After Ileocolonic Resection: A Multicenter Retrospective Cohort Study. 2021 ,		2

139	A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn's Disease: A Phase II, Open-Label Study. 2021 , 35, 325-336		3
138	Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. 2021 , 56, 489-526		40
137	Utility of the combined use of 3 serologic markers in the diagnosis and monitoring of chronic enteropathies in dogs. 2021 , 35, 1306-1315		3
136	Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study. 2021 , 45, 165-165		1
135	Inflammatory bowel disease and the gut microbiota. 2021 , 1-11		1
134	Overuse of Tuberculosis Surveillance Testing in Patients With Inflammatory Bowel Disease Compared to Non-IBD Patients on Biologic Therapy. 2021 , 3,		0
133	Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing). 2021 , 22, 298-317		10
132	Physical activity and quality of life of patients with inflammatory bowel disease. 2021 , 100, e26290		2
131	Inflammatory bowel disease in primary immunodeficiency disorders is a heterogeneous clinical entity requiring an individualized treatment strategy: A systematic review. 2021 , 20, 102872		1
130	Long-term Disease Course of Crohn's Disease: Changes in Disease Location, Phenotype, Activities, and Predictive Factors. <i>Gut and Liver</i> , 2021 ,	4.8	0
129	Biomimetic immunomodulation strategies for effective tissue repair and restoration. 2021 , 179, 113913		4
128	Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn's disease and ulcerative colitis. <i>Annals of Gastroenterology</i> , 2021 , 34, 612-624	2.2	0
127	Granulomatous Dermatitis and Others. 2020 , 137-198		1
126	Colonoscopy. 2015 , 41-112		0
125	Self-Management Techniques in IBD. 2016 , 55-70		6
124	Concepts in Inflammatory Bowel Disease Management. 2019 , 1888-1918		1
123	Encapsulation of Escherichia coli strain Nissle 1917 in a chitosan-alginate matrix by combining layer-by-layer assembly with CaCl cross-linking for an effective treatment of inflammatory bowel diseases. 2020 , 189, 110818		11
122	Established Management Paradigms in IBD: Treatment Targets and Therapeutic Tools. 2016 , 3, 8-16		6

121	Budesonide-related adrenal insufficiency. 2015 , 2015,	7
120	Azathioprine is more effective than mesalazine at preventing recurrent bowel obstruction in patients with ileocecal Crohn's disease. 2014 , 20, 2165-70	8
119	Host genetics and environmental factors regulate ecological succession of the mouse colon tissue-associated microbiota. 2012 , 7, e30273	34
118	Identification of novel predictor classifiers for inflammatory bowel disease by gene expression profiling. 2013 , 8, e76235	44
117	Coping strategies, satisfaction with life, and quality of life in Crohn's disease: A gender perspective using structural equation modeling analysis. 2017 , 12, e0172779	16
116	Comparison of anti-inflammatory activities of an anthocyanin-rich fraction from Portuguese blueberries (<i>Vaccinium corymbosum</i> L.) and 5-aminosalicylic acid in a TNBS-induced colitis rat model. 2017 , 12, e0174116	42
115	Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States. 2017 , 12, e0175099	21
114	Hospitalizations for Crohn's Disease - United States, 2003-2013. 2017 , 66, 377-381	22
113	THE INFLAMMATORY BOWEL DISEASE-FATIGUE PATIENT SELF-ASSESSMENT SCALE: TRANSLATION, CROSS-CULTURAL ADAPTATION AND PSYCHOMETRIC PROPERTIES OF THE BRAZILIAN VERSION (IBD-F BRAZIL). 2020 , 57, 50-63	2
112	Bridges to excellence quality indicators in inflammatory bowel disease (IBD): differences between IBD and non-IBD gastroenterologists. <i>Annals of Gastroenterology</i> , 2017 , 30, 192-196	2.2 7
111	Mobile Phone Apps for Inflammatory Bowel Disease Self-Management: A Systematic Assessment of Content and Tools. 2016 , 4, e13	48
110	Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF- α) inhibitors [LISA-TRACKER \square enzyme-linked immunosorbent assay (ELISA) kits, TNF- α blocker ELISA kits and Promonitor \square ELISA kits] versus standard care in patients with Crohn's disease: a randomised controlled trial. 2015 , 22, 1-10	17
109	A Brazilian experience of the self transglutaminase-based test for celiac disease case finding and diet monitoring. 2009 , 15, 4423-8	13
108	Capsule endoscopy in suspected small bowel Crohn's disease: economic impact of disease diagnosis and treatment. 2009 , 15, 5685-92	18
107	Old-age inflammatory bowel disease onset: a different problem?. 2011 , 17, 2734-9	51
106	Epidemiology and clinical course of Crohn's disease: results from observational studies. 2012 , 18, 1723-31	81
105	Interventions and targets aimed at improving quality in inflammatory bowel disease ambulatory care. 2013 , 19, 6375-82	8
104	Use of exclusive enteral nutrition in adults with Crohn's disease: a review. 2013 , 19, 7652-60	82

103	Thiopurine-methyltransferase variants in inflammatory bowel disease: prevalence and toxicity in Brazilian patients. 2014 , 20, 3327-34	12
102	Tools for primary care management of inflammatory bowel disease: do they exist?. 2015 , 21, 4457-65	17
101	Disease monitoring in inflammatory bowel disease. 2015 , 21, 11246-59	86
100	Influence of environmental factors on the onset and course of inflammatory bowel disease. 2016 , 22, 1088-100	28
99	Impact of vitamin D on the hospitalization rate of Crohn's disease patients seen at a tertiary care center. 2017 , 23, 2539-2544	7
98	Endoscopic management of Crohn's strictures. 2018 , 24, 1859-1867	27
97	Magnetic resonance imaging and Crohn's disease endoscopic index of severity: Correlations and concordance. 2018 , 24, 2279-2290	2
96	Obesity is Associated With Poor Surgical Outcome in Crohn's Disease. 2013 , 6, 85-90	6
95	Immunoglobulin Transport during Gestation in Domestic Animals and HumansA Review. 2014 , 04, 323-336	33
94	Hepatic manifestations of non-steroidal inflammatory bowel disease therapy. 2015 , 7, 2716-28	4
93	Combination therapy for inflammatory bowel disease. 2017 , 8, 103-113	21
92	5-Aminosalicylates to maintain remission in Crohn's disease: Interpreting conflicting systematic review evidence. 2017 , 8, 99-102	4
91	Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease. <i>Gut and Liver</i> , 2020 , 14, 7-19	4.8 7
90	Guidelines for the Management of Crohn's Disease. 2012 , 10, 26	9
89	Efficacy of Thiopurines in Biologic-Naive Japanese Patients With Crohn's Disease: A Single-Center Experience. 2015 , 13, 266-73	4
88	Role of Advanced Endoscopic Imaging Techniques in the Management of Inflammatory Bowel Disease. 2017 , 50, 424-428	4
87	Examining perceptions of the usefulness and usability of a mobile-based system for pharmacogenomics clinical decision support: a mixed methods study. 2016 , 4, e1671	24
86	Managing Crohn's Disease 2009. 2009 , 42, 28	

- 85 Inflammatory Bowel Disease. **2010**, 61-79 1
- 84 A Pityrosporum Fungal Infection Following Infliximab Therapy in a Crohn's Disease Patient. **2010**, 8, 177
- 83 Surgical Conditions Presenting with Diarrhea. **2010**, 237-263
- 82 Inflammatory Bowel Disease. **2010**, 463-467.e1
- 81 Crohn's Disease: Surgical Management. **2011**, 499-516 1
- 80 Inflammatory bowel disease. **2011**, 190-205
- 79 State-of-the-Art Medical Treatment of the Adult Patient with IBD: The Biological Therapies. **2011**, 111-121
- 78 Tuberculose pleural após uso de adalimumabe na doença de Crohn: relato de caso. **2011**, 31, 85-88
- 77 Inflammatory bowel disease. **2011**, 86-92
- 76 Recent Trends of Infliximab Treatment for Crohn's Disease. **2012**, 15, 19
- 75 Why do we Still Use 5-ASAs in Crohn's Disease?. 73-76
- 74 A likely diagnosis of Crohn's disease in a 95-year-old woman. **2012**, 2012,
- 73 A Primer on IBD: Phenotypes, Diagnosis, Treatment, and Clinical Challenges. **2013**, 3-21
- 72 Surgery for Inflammatory Bowel Disease. **2013**, 2009-2018
- 71 Crohn's disease activity assessed by Doppler sonography: the role of aortic flow parameters. **2013**, 68, 457-62 3
- 70 Appropriate administration timing and clinical indications of thiopurine in Crohn's disease. **2014**, 63, 194-8
- 69 Body Mass Index Is Associated With Mucosal Disease in Crohn's: Results of a Case-Control Study. **2014**, 7, 111-117
- 68 Retrospective cohort study of anti-tumor necrosis factor agent use in a veteran population. **2014**, 2, e385

- 67 Enfermedad de Crohn. Enfoque diagnóstico y terapéutico de las primeras visitas. **2014**, 29, 404-416 o
- 66 What Is the Best Possible Therapy for My Crohn's Disease? State-of-the-Art Therapy for Newly Diagnosed Crohn's Disease. **2015**, 59-71
- 65 Chapter 25. Gastrointestinal Diseases. **2015**,
- 64 Obesity and Outcome of Crohn's Associated Perianal Fistula Surgery: A Case-Control Study. **2015**, 8, 291-295 1
- 63 Gallbladder Polyps, Surgical Indications According to their Size and Morphology. **2015**, 2,
- 62 Barriers to Successful Outcomes in Patients with Inflammatory Bowel Diseases. **2016**, 1-17
- 61 Crohn's Disease: Clinical Manifestations and Management. 1418-1449
- 60 Radiological Follow-Up of Inflammatory Bowel Diseases. **2016**, 137-146
- 59 Specifics and Pitfalls in Diagnosis of Inflammatory Bowel Diseases. **2016**, 1-9
- 58 Compendium of Inflammatory Diseases. **2016**, 1255-1265
- 57 Celiac Disease and Inflammatory Bowel Disease. 983-989
- 56 GI Disease Nutrition Management: Inflammatory Bowel Disease. **2016**, 43-55
- 55 Chapter 25: Gastrointestinal Diseases. **2017**,
- 54 Cirugía de las complicaciones anorrectales de la enfermedad de Crohn. **2018**, 34, 1-16
- 53 Chirurgia delle complicanze anorettali della malattia di Crohn. **2018**, 24, 1-16
- 52 Crohn Disease and Its Surgical Management. **2019**, 864-885
- 51 Inflammatory Bowel Disease. **2019**, 123-129
- 50 Surgery for Crohn Disease. **2019**, 1941-1950

49	IBD: Who Can Go Home? Who Should Be Admitted?. 2019 , 317-319		
48	Acute Complications of Inflammatory Bowel Disease. 2020 , 247-259		
47	[From Axial Spondyloarthritis to Osteoporosis - Spectrum of Skeletal Involvement in Inflammatory Bowel Diseases]. <i>Praxis</i> , 2019 , 108, 799-806	0.1	1
46	İnflamatuvar barsak hastalıklarında epidemiyolojik özellikler ve hastalık farkında mıyız? Türkiye kesitsel bir çalışma. <i>Akademik Gastroenteroloji Dergisi</i> , 1-7		
45	The changing landscape of surgery for Crohn's disease. <i>Seminars in Colon and Rectal Surgery</i> , 2020 , 31, 100740	0.3	
44	Pharmacology of Aging. 2020 , 1-30		
43	Colonoscopy. 2021 , 45-74		
42	Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries. <i>Gut and Liver</i> , 2020 , 14, 685-698	4.8	2
41	Biologic Therapies for Crohn's Disease: Update from the 2009 ACG Meeting. <i>Gastroenterology and Hepatology</i> , 2010 , 6, 4-16	0.7	2
40	New Data on the Use of Biologic Agents for Crohn's Disease and Ulcerative Colitis: Highlights from the 2009 CCFA Advances in IBD Meeting. <i>Gastroenterology and Hepatology</i> , 2010 , 6, 4-16	0.7	1
39	Highlights from digestive disease week 2010. <i>Gastroenterology and Hepatology</i> , 2010 , 6, 1-16	0.7	
38	Crohn's disease: the first visit. <i>Gastroenterology and Hepatology</i> , 2011 , 7, 163-9	0.7	5
37	Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update. <i>Clinical and Experimental Gastroenterology</i> , 2009 , 2, 149-61	3.1	4
36	Targeting mucosal healing in Crohn's disease. <i>Gastroenterology and Hepatology</i> , 2011 , 7, 374-80	0.7	7
35	Crohn's disease diagnosis following discovery of in situ follicular lymphoma. <i>Gastrointestinal Cancer Research: GCR</i> , 2011 , 4, 184-7		1
34	Retained pill camera at an entero-uracho-vesical fistula site in a patient with Crohn's disease. <i>Hawaii Journal of Medicine & Public Health: A Journal of Asia Pacific Medicine & Public Health</i> , 2013 , 72, 186-9	0.6	2
33	Quality improvement in inflammatory bowel disease. <i>Gastroenterology and Hepatology</i> , 2013 , 9, 286-92	0.7	21
32	Electrolyte and acid-base disorders in inflammatory bowel disease. <i>Annals of Gastroenterology</i> , 2013 , 26, 23-28	2.2	32

31	Refractory pancolitis: a novel presentation of idiopathic myointimal hyperplasia of mesenteric veins. <i>Gastroenterology and Hepatology</i> , 2012 , 8, 696-700	0.7	4
30	Environmental influences on the onset and clinical course of Crohn's disease-part 2: infections and medication use. <i>Gastroenterology and Hepatology</i> , 2013 , 9, 803-10	0.7	4
29	Addressing Costs and Continuity of Care through Innovative Solutions for Infused Therapies: A Collaborative Experience with Infliximab. <i>American Health and Drug Benefits</i> , 2011 , 4, 39-46	1.7	3
28	What is the impact of age on adult patients with inflammatory bowel disease?. <i>Clujul Medical</i> , 2013 , 86, 3-9		9
27	Effectiveness and risk associated with infliximab alone and in combination with immunosuppressors for Crohn's disease: a systematic review and meta-analysis. <i>International Journal of Clinical and Experimental Medicine</i> , 2015 , 8, 4846-54		2
26	Clinical profiles of moderate and severe Crohn's disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines. <i>Annals of Gastroenterology</i> , 2015 , 28, 417-25	2.2	5
25	Placental inflammation is not increased in inflammatory bowel disease. <i>Annals of Gastroenterology</i> , 2015 , 28, 457-63	2.2	2
24	Inflammatory bowel disease: can omega-3 fatty acids really help?. <i>Annals of Gastroenterology</i> , 2016 , 29, 37-43	2.2	39
23	Fecal Microbiota Transplantation for Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2016 , 12, 374-9	0.7	21
22	Vedolizumab as a Treatment for Crohn's Disease and Ulcerative Colitis. <i>Gastroenterology and Hepatology</i> , 2014 , 10, 793-800	0.7	4
21	Managing Crohn's Disease during Pregnancy. <i>Medica</i> , 2016 , 11, 221-226		1
20	Faecal microbiota transplantation: looking beyond clostridium difficile infection at inflammatory bowel disease. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2018 , 11, 1-8	1.2	5
19	A Noninvasive Method to Assess Mucosal Healing in Patients* With Crohn's Disease. <i>Gastroenterology and Hepatology</i> , 2018 , 14, 1-12	0.7	3
18	An Unusual Presentation of Crohn's Disease Diagnosed Following Accidental Ingestion of Fruit Pits: Report of Two Cases and Review of the Literature.. <i>Life</i> , 2021 , 11,		3
17	Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study. <i>Gastroenterologia Y Hepatologia (English Edition)</i> , 2022 , 45, 165-176	0.1	
16	Oral microbiome of Crohn's Disease patients with and without oral manifestations.. <i>Journal of Crohn's and Colitis</i> , 2022 ,	1.5	
15	Surgical Planning in Penetrating Abdominal Crohn's Disease.. <i>Frontiers in Surgery</i> , 2022 , 9, 867830	2.3	
14	Effects of Different Biological Therapies on S1/S2 Antibody Response to SARS-CoV-2 Vaccination in a Cohort of Patients with Inflammatory Bowel Disease. <i>Vaccines</i> , 2022 , 10, 1077	5.3	

- 13 Clinical implication of radiologic complete remission on Crohn's Disease: Compared with endoscopic remission. **2022**, 155, 110469 ○
- 12 Adalimumab for induction of remission in patients with Crohn's disease: a systematic review and meta-analysis. **2022**, 27, ○
- 11 Preventing Collateral Damage in the Inflammatory Bowel Disease Patient: Using Disease Assessment and Prognostic Factors to Optimise Clinical Outcomes. 28-33 ○
- 10 Postoperative diarrhea in Crohn's disease: Pathogenesis, diagnosis, and therapy. 11, 7-16 ○
- 9 Inflammatory Bowel Disease in the Childbearing Adult and Newborn. **2023**, 24, 10-23 ○
- 8 Real-world utilization of top-down and step-up therapy and initial costs in Crohn disease. **2022**, 28, 849-861 ○
- 7 Thiopurines; Azathioprine, Mercaptopurine and Thioguanine. **2016**, 1-12 ○
- 6 The Role of Probiotics in Inducing and Maintaining Remission in Crohn's Disease and Ulcerative Colitis: A Systematic Review of the Literature. **2023**, 11, 494 ○
- 5 Evaluation of Crohn's Disease Small-Bowel Mucosal Healing Using Capsule Endoscopy and Usefulness of Leucine-Rich α -Glycoprotein. **2023**, 13, 626 ○
- 4 Systematic review: Individual-level factors and social determinants of health impacting sleep health in individuals with inflammatory bowel disease. ○
- 3 Nitric Oxide, Neutrophil/Lymphocyte, and Platelet/Lymphocyte Ratios as Promising Inflammatory Biomarkers in Complicated Crohn's Disease: Outcomes of Corticosteroids and Anti-TNF- α Therapies. ○
- 2 Surgery for Crohn Disease. **2013**, 364-382 ○
- 1 Inflammation-Driven Colorectal Cancer Associated with Colitis: From Pathogenesis to Changing Therapy. **2023**, 15, 2389 ○